MedTrace Logo

Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy

NCT05865301 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2026-02-09

No results posted yet for this study

Summary

To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozogamicin.

Conditions

  • Lymphoid Leukemia

Interventions

OTHER

Questionnaire for patients receiving therapy

Questionnaires will be given (at baseline, 1, 3, 6, and 12 months post CAR infusion) including baseline demographics, individual/family and neighborhood socioeconomic data, measures of household material hardship (housing and transportation insecurity, household energy and food insecurity), barriers to care at the CAR T cell institution, as well as patient reported outcomes following Kymriah infusion.

Sponsors & Collaborators

  • Pediatric Oncology Experimental Therapeutic Investigators Consortium

    collaborator UNKNOWN

  • Stanford University

    lead OTHER

Principal Investigators

  • Liora Schultz, M.D · Stanford University

Eligibility

Max Age
26 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-29
Primary Completion
2026-04-30
Completion
2038-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05865301 on ClinicalTrials.gov